SPECT-Untersuchungen mit dem ¹²³I-markierten Dopamintransporter-Liganden FP-CIT (DaTSCAN^TM) ^[*]

Zusammenfassung

Die S1-Leitlinie soll bei der Indikationsstellung, Durchführung, Interpretation und Befundung von SPECT-Untersuchungen des Dopamintransporters (DAT) mit DaTSCAN^TM unterstützen. Gegenüber der Vorgängerversion von 2007 berücksichtigt die vorliegende Aktualisierung und Überarbeitung die neuere wissenschaftliche Literatur, zwischenzeitlich veröffentlichte Guidelines der europäischen (EANM) und amerikanischen Fachgesellschaften (SNM), sowie die aktuelle Fassung der S3-Leitlinie „Idiopathisches Parkinson-Syndrom“ der Deutschen Gesellschaft für Neurologie. Zudem finden neue technische Möglichkeiten Berücksichtigung.

Abstract

The aim of the S1 guideline is to assist in establishing the indication and in performing, interpreting and reporting SPECT investigations of the dopamine transporter (DAT) with DaTSCAN^TM. Compared to the preceding version dated from 2007 the current update considers relevant new publications, the guidelines of the European (EANM) and Society of Nuclear Medicine (SNM), and the current version of the S3 guideline of the German Society of Neurology on „Idiopathic Parkinsonsian Syndrome“. In addition new technical developments are incorporated.

Schlüsselwörter

Dopamintransporter - SPECT - I-123 FP-CIT - Parkinson-Syndrome - Demenz mit Lewykörperchen

Key words

Dopamine transporter - SPECT - I-123 FP-CIT - parkinsonian syndromes - dementia with Lewy-bodies

^* Stand: 5/2017 – AWMF-Registernummer: 031–037

• Literatur

• 1 Benamer TS, Patterson J, Grosset DG. et al. [¹²³I]-FP-CIT SPECT imaging: the [¹²³I]-FP-CIT study group. Mov Disord 2000; 15: 503-510
• 2 Booij J, Kemp P. Dopamine transporter imaging with [¹²³I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008; 35: 424-438
• 3 Booij J, Sokole EB, Stabin MG. et al. Human biodistribution and dosimetry of [¹²³I]FP-CIT a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998; 25: 24-30
• 4 Brigo F, Turri G, Tinazzi M. ¹²³I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. J Neurol Sci 2015; 359: 161-171
• 5 Buchert R, Lange C, Apostolova I. et al. Dopamintransporter-SPECT mit [¹²³I] FP-CIT: Empfehlungen für die visuelle Beurteilung. Nuklearmediziner 2015; 38: 40-47
• 6 Darcourt J, Booij J, Tatsch K. et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010; 27: 443-50
• 7 Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D. et al. Clinical features and ¹²³I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease. Eur J Nucl Med Mol Imaging 2010; 37: 556-564
• 8 Djang DS, Janssen MJ, Bohnen N. et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med 2012; 53: 154-63
• 9 Gaig C, Marti MJ, Tolosa E. et al. ¹²³I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord 2006; 21: 1994-1998
• 10 Grosset DG, Tatsch K, Oertel WH. et al. Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane ¹²³I injection (DaTscan). J Nucl Med 2014; 55: 1281-1287
• 11 Lange C, Seese A, Schwarzenbock S. et al. CT-based attenuation correction in I-123-ioflupane SPECT. PLoS One 2014; 9: e108328
• 12 Lapa C, Spehl TS, Brumberg J. et al. Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. Am J Nucl Med Mol Imaging 2015; 5: 278-286
• 13 Lee CS, Samii A, Sossi V. et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 2000; 47: 493-503
• 14 Nikolaus S, Antke C, Hautzel H. et al. Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies. Nuklearmedizin 2016; 55: 21-28
• 15 OʼBrien JT, Oertel WH, McKeith IG. et al. Is Ioflupane I-123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open 2014; 4 (07) e005122 doi: 10.1136/bmopen-2014–005122
• 16 Papathanasiou ND, Boutsiadis A, Dickson J. et al. Diagnostic accuracy of I-123 FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 2012; 18: 225-229
• 17 Tatsch K, Bartenstein P, Brust P. et al. SPECT-Untersuchungen mit dem I-123 markierten Dopamintransporter Liganden FP-CIT (DaTSCAN) 2007; AWMF-Reg.-Nr. 031/037.
• 18 Thomsen G, Knudsen GM, Jensen PS. et al. No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [¹²³I]FP-CIT (DaTSCAN) and SPECT EJNMMI Res 201. 3: 39
• 19 van de Giessen E, Hesse S, Caan MW. et al. No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. Neuroimage 2013; 64: 61-67
• 20 Varrone A, Dickson JC, Tossici-Bolt L. et al. European multicentre database of healthy controls for [¹²³I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 2013; 40: 213-227
• 21 Zijlmans J, Evans A, Fontes F. et al. [¹²³I] FP-CIT SPECT study in vascular parkinsonism and Parkinson’s disease. Mov Disord 2007; 22: 1278-1285